Hepatobiliary Surgery Division, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.
Department of Anesthesiology and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Updates Surg. 2021 Apr;73(2):359-377. doi: 10.1007/s13304-021-01006-6. Epub 2021 Feb 22.
Most surgeons have traditionally been reluctant toward minimally-invasive surgery for bile duct tumors. This study aimed to perform a systematic literature review on perioperative and oncologic results of pure laparoscopic and robotic curative-intent surgery for hilar cholangiocarcinoma. According to the PRISMA statement, a systematic review was conducted into Pubmed, EMBASE and Cochrane. A critical appraisal of study was performed according to the Joanna Briggs Institute tools. Nineteen studies (12 on pure laparoscopy and 7 on robotics) were included: 7 case reports, 9 case series, 3 case-control (193 patients). The pooled conversion, morbidity, biliary leak and mortality rates were 5.5%, 43%, 16.4% and 4%. The weighted mean of operative time, blood loss and postoperative stay were 388 min, 446 mL and 14 days. For pure laparoscopy, the pooled R0 rate was 86%; overall survival and disease-free survival rates ranged from 85 to 100% and from 80 to 100% (median observation time 6-18 months). For robotic surgeries, the pooled R0 rate was 69% and overall survival rates ranged from 90 to 100% (median observation time 5-15 months). Case reports were overall of high quality, case series of moderate / high-quality, case-control studies ranged from low to high quality. In selected patients, minimally-invasive surgery for Klatskin tumors appears feasible, safe, satisfactory for perioperative outcomes and adequate for oncologic results. However, the results are based on few studies, limited in patient numbers and with allocation criteria more restrictive than open, reporting short follow-up and mainly with non-comparative design: evidence of higher quality is recommended.
大多数外科医生传统上对胆管肿瘤的微创手术持保留态度。本研究旨在对腹腔镜和机器人根治性手术治疗肝门部胆管癌的围手术期和肿瘤学结果进行系统文献回顾。根据 PRISMA 声明,对 Pubmed、EMBASE 和 Cochrane 进行了系统评价。根据 Joanna Briggs 研究所的工具对研究进行了批判性评估。共纳入 19 项研究(12 项为单纯腹腔镜,7 项为机器人):7 篇病例报告,9 篇病例系列,3 篇病例对照(193 例)。汇总转化率、发病率、胆漏和死亡率分别为 5.5%、43%、16.4%和 4%。手术时间、出血量和术后住院时间的加权平均值分别为 388 分钟、446 毫升和 14 天。对于单纯腹腔镜,汇总的 R0 率为 86%;总生存率和无病生存率范围为 85%至 100%和 80%至 100%(中位观察时间 6-18 个月)。对于机器人手术,汇总的 R0 率为 69%,总生存率范围为 90%至 100%(中位观察时间 5-15 个月)。病例报告总体质量较高,病例系列为中/高质量,病例对照研究质量从低到高不等。在选择的患者中,微创治疗 Klatskin 肿瘤似乎是可行的、安全的,围手术期结果令人满意,肿瘤学结果也足够。然而,这些结果基于少数研究,患者数量有限,且分配标准比开放手术更严格,报告的随访时间较短,主要采用非对照设计:建议提供更高质量的证据。